Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free NTRA Stock Alerts $88.61 +3.33 (+3.90%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$85.10▼$89.2850-Day Range$68.40▼$97.4852-Week Range$36.90▼$98.82Volume1.12 million shsAverage Volume1.22 million shsMarket Capitalization$10.70 billionP/E RatioN/ADividend YieldN/APrice Target$86.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Natera alerts: Email Address Natera MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2.5% Downside$86.40 Price TargetShort InterestHealthy5.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 15 Articles This WeekInsider TradingSelling Shares$36.30 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.35) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.60 out of 5 starsMedical Sector656th out of 909 stocksMedical Laboratories Industry17th out of 20 stocks 2.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.18% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Natera has recently decreased by 21.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 2.6 News and Social Media Coverage News SentimentNatera has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Natera this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -35% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,295,674.00 in company stock.Percentage Held by InsidersOnly 9.42% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.35) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -23.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -23.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 13.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Natera Stock (NASDAQ:NTRA)Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesApril 19, 2024 | insidertrades.comSteven Leonard Chapman Sells 6,816 Shares of Natera, Inc. (NASDAQ:NTRA) StockApril 6, 2024 | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 26,700 Shares of StockApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,378 SharesMarch 31, 2024 | insidertrades.comJonathan Sheena Sells 447 Shares of Natera, Inc. (NASDAQ:NTRA) StockApril 23, 2024 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Given Average Rating of "Buy" by AnalystsApril 22, 2024 | businesswire.comNatera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsApril 19, 2024 | americanbankingnews.comSolomon Moshkevich Sells 80,000 Shares of Natera, Inc. (NASDAQ:NTRA) StockApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 18, 2024 | investing.comNatera CEO sells shares worth over $630kApril 18, 2024 | finance.yahoo.comInsider Sell: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)April 17, 2024 | msn.comNatera (NTRA) Price Target Increased by 7.38% to 102.96April 16, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Given New $100.00 Price Target at The Goldman Sachs GroupApril 16, 2024 | finance.yahoo.comNatera, Inc. (NTRA) Interactive Stock Chart - Yahoo FinanceApril 12, 2024 | finance.yahoo.comEstimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)April 11, 2024 | businesswire.comNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationApril 10, 2024 | stockhouse.comNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera(TM) Heart dd-cfDNA Test for Heart Transplant RecipientsApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Natera (NTRA) and Mirum Pharmaceuticals (MIRM)April 8, 2024 | businesswire.comNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant RecipientsApril 5, 2024 | benzinga.comCracking The Code: Understanding Analyst Reviews For NateraApril 5, 2024 | msn.comNatera upgraded at Bernstein on gross margin trajectoryApril 5, 2024 | markets.businessinsider.comNatera Announces Positive Results From IMvigor011 Phase III Study In Muscle-Invasive Bladder CancerApril 5, 2024 | msn.comIs Natera (NTRA) On The Cusp Of Being Cash Flow Positive?April 5, 2024 | businesswire.comNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder CancerApril 5, 2024 | finance.yahoo.comInsider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)April 1, 2024 | finance.yahoo.comNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial CancerMarch 31, 2024 | investing.comNatera CFO exercises options and sells shares worth over $82,000See More Headlines Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/22/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$86.40 High Stock Price Target$120.00 Low Stock Price Target$66.00 Potential Upside/Downside-2.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-40.16% Pretax Margin-40.14% Return on Equity-62.19% Return on Assets-31.88% Debt Debt-to-Equity Ratio0.37 Current Ratio4.10 Quick Ratio3.96 Sales & Book Value Annual Sales$1.08 billion Price / Sales9.88 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book13.91Miscellaneous Outstanding Shares120,760,000Free Float109,383,000Market Cap$10.70 billion OptionableOptionable Beta1.37 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 45)CEO & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 44)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 55)Secretary & Chief Legal Officer Comp: $566.03kMr. John FeskoPresident & Chief Business OfficerMr. Jonathan Sheena M.Eng. (Age 51)Co-Founder & Director Comp: $293.91kMs. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMore ExecutivesKey CompetitorsExact SciencesNASDAQ:EXASQuest DiagnosticsNYSE:DGXLaboratory Co. of AmericaNYSE:LHFortreaNASDAQ:FTRERadNetNASDAQ:RDNTView All CompetitorsInsiders & InstitutionsRaymond James Financial Services Advisors Inc.Bought 28,493 shares on 4/23/2024Ownership: 0.024%EFG Asset Management Americas Corp.Sold 2,913 shares on 4/22/2024Ownership: 0.003%Maryland State Retirement & Pension SystemBought 857 shares on 4/20/2024Ownership: 0.007%Sumitomo Mitsui Trust Holdings Inc.Bought 371,271 shares on 4/19/2024Ownership: 0.307%Handelsinvest InvesteringsforvaltningSold 1,878 shares on 4/19/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions NTRA Stock Analysis - Frequently Asked Questions Should I buy or sell Natera stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares. View NTRA analyst ratings or view top-rated stocks. What is Natera's stock price target for 2024? 14 Wall Street analysts have issued 12-month price objectives for Natera's stock. Their NTRA share price targets range from $66.00 to $120.00. On average, they predict the company's share price to reach $86.40 in the next year. This suggests that the stock has a possible downside of 2.5%. View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts. How have NTRA shares performed in 2024? Natera's stock was trading at $62.64 at the beginning of 2024. Since then, NTRA stock has increased by 41.5% and is now trading at $88.61. View the best growth stocks for 2024 here. Are investors shorting Natera? Natera saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,250,000 shares, a decline of 21.4% from the March 15th total of 7,950,000 shares. Based on an average trading volume of 1,520,000 shares, the short-interest ratio is currently 4.1 days. View Natera's Short Interest. When is Natera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NTRA earnings forecast. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings data on Wednesday, February, 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. The medical research company earned $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative trailing twelve-month return on equity of 62.19%. What ETFs hold Natera's stock? ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Genomics & Biotechnology ETF (GNOM), Alger Mid Cap 40 ETF (FRTY), Pinnacle Focused Opportunities ETF (FCUS), Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Alger 35 ETF (ATFV). What guidance has Natera issued on next quarter's earnings? Natera issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). When did Natera IPO? Natera (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.71%), Sumitomo Mitsui Trust Holdings Inc. (0.31%), Artemis Investment Management LLP (0.19%), Raymond James Financial Services Advisors Inc. (0.02%), Maryland State Retirement & Pension System (0.01%) and Banque Cantonale Vaudoise (0.01%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Solomon Moshkevich, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTRA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
